After the success of PSMA-targeted radiopharmaceuticals for prostate cancer imaging and therapy, the Auger emitter 125I was used to develop [125I]I-DCIBzL (20), which showed excellent antitumor efficacy in prostate cancer therapy compared with phosphate-buffered saline controls. Here, FOLH1 is linked to prostate cancer.